Informations générales (source: ClinicalTrials.gov)
Multicentric Cohort of HIV-1 (Human Immunodeficiency Virus 1) Primary Infection Cohort ANRS CO6 PRIMO (PRIMO)
Observational
ANRS, Emerging Infectious Diseases (Voir sur ClinicalTrials)
octobre 1996
septembre 2025
29 juin 2024
Open, prospective, multicenter French cohort study enrolling subjects aged of 15 years or
more, during or immediately after HIV-1 primary infection. This cohort was organized from
the outset to be highly multidisciplinary, bringing together immunologists, virologists,
clinicians and epidemiologists.
Etablissements
| Les établissements d'Île-de-France ayant mis à jour leurs données Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| CHI DE CRETEIL | Valérie GARRAIT | 29/03/2024 01:27:26 | Contacter | ||
| HOPITAL NOVO | BLUM | 04/07/2024 11:04:55 | Contacter | ||
| Les établissements d'Île-de-France dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
| HOPITAL FOCH | vendredi 11 mars 2022 | Contact (sur clinicalTrials) | |||
| Les établissements sans correspondance certaine dans le répertoire FINESS dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
| Laurence Meyer - 94276 - Le Kremlin Bicêtre - France | Laurence Ms Meyer, Professor | Contact (sur clinicalTrials) | |||
Critères
Tous
Inclusion Criteria:
- symptomatic or asymptomatic HIV-1 primary infection.
- Infection date based on one of the following criteria:
1. Positive p24 antigenemia or detectable plasma HIV RNA with a negative ELISA
within the previous six weeks.
2. Positive p24 antigenemia or detectable plasma HIV RNA with a positive ELISA and
negative Western Blot within the previous six weeks.
3. Positive p24 antigenemia or detectable plasma HIV RNA or positive ELISA with
incompleted Western Blot (no anti-p34 and/or anti-p68) within the previous six
weeks.
4. Positive ELISA with a negative ELISA within the last three months.
- Age≥ 15 years old at the enrollment.
- Naive of antiretroviral treatment except for transient treatment taken in the
context of PMTCT, Pre-exposition prophylaxis or Post Exposition Prophylaxis.
- Affiliate or beneficiary of a social security system (State Medical Assistance is
not a social security scheme).
- symptomatic or asymptomatic HIV-1 primary infection.
- Infection date based on one of the following criteria:
1. Positive p24 antigenemia or detectable plasma HIV RNA with a negative ELISA
within the previous six weeks.
2. Positive p24 antigenemia or detectable plasma HIV RNA with a positive ELISA and
negative Western Blot within the previous six weeks.
3. Positive p24 antigenemia or detectable plasma HIV RNA or positive ELISA with
incompleted Western Blot (no anti-p34 and/or anti-p68) within the previous six
weeks.
4. Positive ELISA with a negative ELISA within the last three months.
- Age≥ 15 years old at the enrollment.
- Naive of antiretroviral treatment except for transient treatment taken in the
context of PMTCT, Pre-exposition prophylaxis or Post Exposition Prophylaxis.
- Affiliate or beneficiary of a social security system (State Medical Assistance is
not a social security scheme).
- Inability to give informed consent.
- Predictable difficult follow-up.
- Contraindication to repeated blood samples.
- Under protection (saving) of justice
- Life-threatening pathology (deferred inclusion is possible)